No Data
No Data
Sichuan Goldstone (300434.SZ): Does not involve the production of PBO materials
Goldstone Pharmaceuticals (300434.SZ) stated on the investor interaction platform on September 12 that the company is not involved in the production of PBO materials and is currently conducting research and development work on vacuum coating equipment for the surface metallization treatment of PBO materials.
We Think You Can Look Beyond Sichuan Goldstone Asia Pharmaceutical's (SZSE:300434) Lackluster Earnings
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report Summary
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report
Sichuan Goldstone Pharmaceuticals (300434.SZ) released its performance for the first half of the year, with a net income of 39.2022 million yuan, a decrease of 74.83%.
Sichuan Goldstone (300434.SZ) released its 2024 interim report, and the company's revenue was 0.522 billion...
Sichuan Goldstone (300434.SZ): The net income in the first half of the year was 39.2022 million yuan, a year-on-year decrease of 74.83%.
On August 28th, Goldstone Pharmacy (300434.SZ) released its semi-annual report for the year 2024. During the reporting period, the revenue was 0.522 billion yuan, a decrease of 17.64% year-on-year. The net income attributable to the shareholders of the listed company was 39.2022 million yuan, a decrease of 74.83% year-on-year. The net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 37.0364 million yuan, a decrease of 75.25% year-on-year. The basic earnings per share was 0.0976 yuan.
No Data
No Data